On May 3, 2024 Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, reported that new data will be presented at the upcoming AUA, ASCO (Free ASCO Whitepaper) and SNMMI 2024 Annual Meetings, covering clinical results and trials in progress (Press release, Clarity Pharmaceuticals, MAY 3, 2024, View Source [SID1234642582]). The data showcases the extensive scope of Clarity’s Targeted Copper Theranostic (TCT) platform in developing multiple products for imaging and treating cancer patients, with focus on prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, "The AUA, ASCO (Free ASCO Whitepaper) and SNMMI Annual Meetings are among the most prestigious conferences in urology, oncology and nuclear medicine, respectively. We are delighted that our data has been accepted for presentation at these world leading conferences. The abstracts accepted for presentations, including two oral presentations, highlight the exciting opportunities for our next-generation TCT radiopharmaceuticals as we continue to generate incredible data on what we strongly believe to be best in class assets for the treatment and diagnosis of cancer.

"We are looking forward to sharing this data as we continue to adhere to the highest standards of clinical research, work with world-class clinical sites and generate exciting results to date while expanding the platform into multiple indications. We are also looking forward to further developing our existing as well as novel TCT products as we get closer to our ultimate goal of improving treatment outcomes for children and adults with cancer."

Data to be presented at 2024 AUA, ASCO (Free ASCO Whitepaper) and SNMMI Annual Meetings
Product Abstract Title Conference
64Cu-SAR-bisPSMA CLARIFY: Positron Emission Tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy, a phase 3 diagnostic study AUA – Oral presentation
Session Date
Sunday, May 5th

Session Time
1:00-3:00 PM CT

Session Title
Clinical Trials in Progress—Cancer

64Cu-SAR-bisPSMA COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy ASCO – Poster presentation
Session Date
Sunday, June 2nd

Session Time
9:00 AM – 12:00 PM CT

Session Title/Track
Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track
Prostate Cancer–Local-Regional Disease

Abstract # 5100

Poster Bd # 506

64Cu-SAR-bisPSMA CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy (a phase 3 diagnostic study) ASCO – Poster presentation
Session Date
Sunday, June 2nd

Session Time
9:00 AM – 12:00 PM CT

Session Title/Track
Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track
Prostate Cancer–Local-Regional Disease

Abstract # TPS5129

Poster Bd # 524a

67Cu-SAR-bisPSMA SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer

ASCO – Poster presentation
Session Date
Sunday, June 2nd

Session Time
9:00 AM – 12:00 PM CT

Session Title/Track
Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track
Prostate Cancer– Advanced/Castrate-Resistant

Abstract # TPS5116

Poster Bd # 517b

64Cu-SAR-bisPSMA COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy SNMMI – Oral presentation
Session Date
Tuesday, June 11th

Session Time
8:00 AM – 9:15 AM ET

Session Title
Prostate Cancer – Radiomics/Data Analysis

67Cu-SAR-bisPSMA SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer SNMMI – Poster presentation
67Cu-SAR-BBN COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate resistant prostate cancer ineligible for therapy with 177Lu-PSMA-617 SNMMI – Poster presentation
64Cu-SAR-BBN SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in PSMA-negative biochemical recurrent prostate cancer patients SNMMI – Poster presentation
Posters and presentations containing study results will be available on Clarity’s official website after their presentation at the 2024 AUA, ASCO (Free ASCO Whitepaper) and SNMMI Annual Meetings: claritypharmaceuticals.com/pipeline/scientific_presentations

Abstracts for the 2024 ASCO (Free ASCO Whitepaper) Annual Meeting will be released on the 23rd of May at 5 PM ET and will be available at the conference website: conferences.asco.org/am/abstracts